Group 1 - The National Medical Products Administration (NMPA) of China has approved the listing application for the ophthalmic product JinYinKang® (Diquafosol Sodium Eye Drops) by the company, with the approval number "国药准字H20254149" [1] - JinYinKang® represents the second ophthalmic drug in the company's pipeline, following JinYinShu®, and aims to provide diverse treatment options for patients with dry eye syndrome [1] - The product works by activating the P2Y2 receptor to stimulate tear and mucin secretion, improving tear film stability and repairing corneal epithelial damage in patients diagnosed with dry eye and associated corneal epithelial defects [1] Group 2 - The company has established a new production base in Dongguan, featuring integrated Blow-Fill-Seal (BFS) technology and a sterile production line, ensuring drug quality and convenience with preservative-free, single-dose packaging [1] - Strategic partnerships with active pharmaceutical ingredient (API) suppliers have been formed to acquire high-quality raw materials at costs below the industry average [1] - The company has expanded its sales team and integrated online and offline channel resources to cover hospitals, pharmacies, and major e-commerce platforms, ensuring rapid market penetration and competitiveness for JinYinKang® [1] Group 3 - The approval of JinYinKang® is expected to create a synergistic effect with JinYinShu®, driving sustained growth in the company's performance [2] - JinYinShu® is targeted to be included in medical insurance coverage by the end of 2025, enhancing the accessibility and market penetration of the company's ophthalmic drugs [2] - The diversification of sales channels and product pipeline will strengthen the company's position in the ophthalmic market [2]
联康生物科技集团(00690)：眼科药物金因康®获批上市